Stock RV6 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Charles River Laboratories International, Inc. Deutsche Boerse AG

Equities

RV6

US1598641074

Real-time Estimate Tradegate
Other stock markets
 12:15:20 10/05/2024 BST 		5-day change 1st Jan Change
214.4 EUR -1.72% Intraday chart for Charles River Laboratories International, Inc. -0.42% -0.56%
12:26pm Evercore ISI Adjusts Price Target on Charles River Laboratories International to $265 From $300 MT
12:24pm Baird Adjusts Price Target on Charles River Laboratories International to $270 From $282 MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Evercore ISI Adjusts Price Target on Charles River Laboratories International to $265 From $300
MT
Baird Adjusts Price Target on Charles River Laboratories International to $270 From $282
MT
Transcript : Charles River Laboratories International, Inc., Q1 2024 Earnings Call, May 09, 2024
Charles River Laboratories International Q1 Non-GAAP Earnings Rise, Revenue Fall; Maintains Full Year 2024 Earnings Guidance
MT
Charles River Laboratories International, Inc. Reports Unaudited Consolidated Impairment Charges for the First Quarter Ended March 30, 2024
CI
Charles River Laboratories International, Inc. Reports Earnings Results for the First Quarter Ended March 30, 2024
CI
Earnings Flash (CRL) CHARLES RIVER LABORATORIES INTERNATIONAL Reports Q1 Adjusted EPS $2.27
MT
Stocks Down Pre-Bell Ahead of Latest Earnings Results; Asia, Europe Churn
MT
Earnings Flash (CRL) CHARLES RIVER LABORATORIES INTERNATIONAL Posts Q1 Revenue $1.01B
MT
(CRL) CHARLES RIVER LABORATORIES INTERNATIONAL Expects Fiscal Year 2024 Adjusted EPS Range $10.90 - $11.40
MT
Charles River: Q1 Earnings Snapshot
AQ
Charles River Laboratories Announces First-Quarter 2024 Results
BU
Charles River Laboratories International, Inc. Revises Financial Guidance for 2024
CI
China trade heats up, UK rates in view
RE
Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
BU
FibroBiologics, Inc. Plans to Collaborate with Charles River Laboratories to Manufacture Fibroblast-Based Spheroids
CI
Charles River Laboratories International : Proxy Supplement Filed April 24, 2024
PU
Charles River Laboratories Files Supplement to Definitive Proxy Statement with the Securities and Exchange Commission
CI
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
BU
Charles River Laboratories International : 2023 Corporate Citizenship Report
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRL Stock
  4. RV6 Stock
  5. News Charles River Laboratories International, Inc.